Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.91 - $41.98
Previous CloseN/A
Volume216.17K
Average Volume (3M)2.49M
Market Cap
$601.75M
Enterprise Value$655.72M
Total Cash (Recent Filing)$100.50M
Total Debt (Recent Filing)$9.70M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
May 06, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.17
Shares Outstanding68,771,866
10 Day Avg. Volume4,746,024
30 Day Avg. Volume2,494,187
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.28
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$33.86Price Target Upside316.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Combination Therapy PotentialThe preliminary data from the vepdegestrant and abemaciclib combination Phase 1b data trial continues to demonstrate vepdeg’s potential as a backbone endocrine therapy.
Drug ApprovalThere is statistical significance in the ESR1 subgroup, which supports approval for vepdegestrant.
Market PotentialVERITAC-2 achieved statistical significance in mPFS for vepdeg vs fulvestrant in the ESR1 mutant population, indicating potential in a specific market.
Bears Say
Market CompetitionUncertainty about the impact to the 2L ESR1m opportunity after AZN announced positive SERENA-6 topline results, which could impact relevance in the 2L setting.
Revenue PotentialArvinas' VERITAC-2 data fails to show a significant benefit in the wild type population, which could have led to a substantial revenue upside.
Trial ResultsThe outlook for vepdegestrant is challenged due to a miss on the VERITAC-2 trial's ITT endpoint.
---
Ownership Overview
2.66% Insiders
25.37% Mutual Funds
0.41% Other Institutional Investors
56.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $7.91 and its highest was $41.98 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $601.75M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is May 06, 2025 which is in 41 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Feb 11, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.955 by $0.325.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -1.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,771,866 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.955. Following the earnings report the stock price went down -6.8%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
---
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.86 (316.48% Upside)
$33.86 (316.48% Upside)
Hedge Fund Trend
Increased
By 54.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $329.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.45%
12-Months-Change
Fundamentals
Return on Equity
-35.41%
Trailing 12-Months
Asset Growth
-16.34%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
---
ARVN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Arvinas, with strong financial results, significant pipeline advancements, and strategic initiatives in place for future growth. Although there are some challenges, such as increased expenses and a leadership change, the overall progress and strategic positioning outweigh these concerns.Read More>---
ARVN Stock 12 Month Forecast
Average Price Target
$33.86
▲(316.48% Upside)
Technical Analysis
Blueprint Medicines
―
CytomX Therapeutics
―
Nurix Therapeutics
―
Kymera Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-15.53%
reiterated a buy rating 16 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -15.53% per trade.
---